Experimental Lilly combination drug tops Zepbound in weight-loss trial

* Lilly says combo drug EloraTZP cut 23.3% of body weight vs 14.8% for Zepbound alone * Company says patient discontinuation rates hit as high as 27% on combo therapy vs 2.9% for tirzepatide alone *

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)